Summit Therapeutics Inc. SMMT
Composite 33/100; the shares have moved about 83% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 7/100 — a strong mark against it.
Balance-sheet strength ranks 87/100 — a strong point in its favour.
Quality ranks 7/100 — a strong mark against it. Valuation ranks 10/100 — a strong mark against it. Momentum ranks 30/100 — a moderate mark against it.
What the company does Summit Therapeutics is a biopharma focused on patient-friendly therapies, with its lead candidate ivonescimab—a bispecific antibody targeting PD-1 and angiogenesis—in Phase III trials for NSCLC and CRC.
Key financials The company shows no revenue or profitability: gross/operating/net margins are 0%, ROE -193% and ROA -102%. Debt/equity is low at 0.03, but liquidity (current ratio 6.96) masks weak fundamentals.
Stock health Momentum is poor: down -35% over 3m, -14% over 6m, and -50% over 12m, with RSI at 42.70. Sideravia scores it “poor quality, fairly valued, weak momentum” (overall 44.3).
Price vs fair value The stock trades at a **discount of 111% versus the 12-month target of 28.36** (analyst count 13). - Analyst target implies >100% upside vs current price (analyst 12-month target 28.36). - Valuation percentile 63.8/100 suggests fair value, despite weak fundamentals (Valuation 63.8). - Negative profitability (ROE -193%, ROA -102%) contrasts with high P/B of 17.30 (ROE -192.5%). - Momentum is deeply negative (-50% over 12m) despite strong Strength score (Momentum 15.6).
Looking forward Clinical readouts for ivonescimab in NSCLC/CRC could materially shift valuation. Analysts project forward P/E of 3.72, implying extreme earnings sensitivity to trial outcomes.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.